Anxiety Over Prospects For Legislative 510(k) Reform Appears To Be Growing
This article was originally published in The Gray Sheet
Executive Summary
FDA and industry are concerned Congress will revise the 510(k) process and defended the program and warned against statutory reforms during a panel discussion at the Food and Drug Law Institute annual meeting in Washington, D.C
You may also be interested in...
510(k) Reform Debate Resurfaces As GAO Completes Mandated Report
The device industry is laying the groundwork to respond to an anticipated government report on the effectiveness of the current 510(k) process
510(k) Reform Debate Resurfaces As GAO Completes Mandated Report
The device industry is laying the groundwork to respond to an anticipated government report on the effectiveness of the current 510(k) process
FDA Device Chief Issues Caution On 510(k)s: Data Requests Could Get Steeper
FDA will demand more comprehensive data from a growing subset of 510(k) submissions, CDRH Director Daniel Schultz suggested at a recent industry meeting